Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BridgeBio Oncology Therapeutics, Inc.BBOT · Entity 5215 | Director | June 16, 2026 | June 18, 2026 |
| BridgeBio Pharma, Inc.BBIO · Entity 3360 | Director | June 22, 2026 | June 24, 2026 |
| CHINOOK THERAPEUTICS, INC.ADRO · Entity 110632 | Director | June 06, 2018 | June 08, 2018 |
| Olema Pharmaceuticals, Inc.OLMA · Entity 613 | Director | November 23, 2020 | November 23, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BridgeBio Oncology Therapeutics, Inc.
Report date June 16, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.73 · Expires 2036-06-15 | Direct | 31,675 |
Reported balance
After 2026-06-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-16 · Grant · Acquired 31,675 · Balance 31,675 F1: The shares underlying the stock option vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting of Stockholders of the Issuer following the date of grant, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the stock option vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting of Stockholders of the Issuer following the date of grant, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date.
BridgeBio Pharma, Inc.
Report date June 22, 2026 · Filed June 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,579 |
Reported balance
After 2026-06-22 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-22 · Grant · Acquired 3,990 · Balance 10,579 F1: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date. F2: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. F3: The Reporting Person previously reported a transfer of 352,290 shares on a Form 4 filed June 25, 2024. The reported transfer did not occur, and no change in beneficial ownership took place at that time. The ownership amounts reported herein reflect the Reporting Person's correct holdings and the transfer described in Footnotes 4 and 5. F4: Excludes 428,976 shares that were previously held directly by the Reporting Person and were transferred to the Reporting Person's trust account on June 3, 2026. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $68.92 · Expires 2036-06-21 | Direct | 5,277 |
Reported balance
After 2026-06-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-22 · Grant · Acquired 5,277 · Balance 5,277 F6: The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date. |
| Common StockSEC Table I · non-derivative | IndirectBy the Francis P. McCormick Rev Trust U/A DTD 1/27/2017 | 756,665 |
Reported balance
Holding disclosure · report date 2026-06-22 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 756,665 F3: The Reporting Person previously reported a transfer of 352,290 shares on a Form 4 filed June 25, 2024. The reported transfer did not occur, and no change in beneficial ownership took place at that time. The ownership amounts reported herein reflect the Reporting Person's correct holdings and the transfer described in Footnotes 4 and 5. F5: Includes 428,976 shares that were previously held directly by the Reporting Person and were transferred to the Reporting Person's trust account on June 3, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.
F2: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F3: The Reporting Person previously reported a transfer of 352,290 shares on a Form 4 filed June 25, 2024. The reported transfer did not occur, and no change in beneficial ownership took place at that time. The ownership amounts reported herein reflect the Reporting Person's correct holdings and the transfer described in Footnotes 4 and 5.
F4: Excludes 428,976 shares that were previously held directly by the Reporting Person and were transferred to the Reporting Person's trust account on June 3, 2026.
F5: Includes 428,976 shares that were previously held directly by the Reporting Person and were transferred to the Reporting Person's trust account on June 3, 2026.
F6: The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.
CHINOOK THERAPEUTICS, INC.
Report date June 06, 2018 · Filed June 08, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.60 · Expires 2028-06-05 | Direct | 20,000 |
Reported balance
After 2018-06-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-06 · Grant · Acquired 20,000 · Balance 20,000 F1: The shares subject to the Option will vest quarterly over one year from the grant date of June 6, 2018, such that the shares will be fully vested on the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the Option will vest quarterly over one year from the grant date of June 6, 2018, such that the shares will be fully vested on the first anniversary of the date of grant.
Olema Pharmaceuticals, Inc.
Report date November 23, 2020 · Filed November 23, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 191,113 |
Reported balance
After 2020-11-23 transaction · row 1
1 source rowRow 1 · 2020-11-23 · Conversion · Acquired 152,891 · Balance 191,113 F1: The shares of Series A Convertible Preferred Stock and Series A-1 Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock and Series A-1 Convertible Preferred Stock automatically converted into shares of Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 84,260 |
Reported balance
After 2020-11-23 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2020-11-23 · Conversion · Acquired 66,326 · Balance 84,260 F1: The shares of Series A Convertible Preferred Stock and Series A-1 Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock and Series A-1 Convertible Preferred Stock automatically converted into shares of Common Stock. F2: The shares are held by the Francis P. McCormick Revocable Trust dated January 27, 2017, of which the Reporting Person is trustee. |
| Series A-1 Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-11-23 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-11-23 · Conversion · Disposed 152,891 · Balance 0 F1: The shares of Series A Convertible Preferred Stock and Series A-1 Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock and Series A-1 Convertible Preferred Stock automatically converted into shares of Common Stock. |
| Series A Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2020-11-23 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-11-23 · Conversion · Disposed 66,326 · Balance 0 F1: The shares of Series A Convertible Preferred Stock and Series A-1 Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock and Series A-1 Convertible Preferred Stock automatically converted into shares of Common Stock. F2: The shares are held by the Francis P. McCormick Revocable Trust dated January 27, 2017, of which the Reporting Person is trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of Series A Convertible Preferred Stock and Series A-1 Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock and Series A-1 Convertible Preferred Stock automatically converted into shares of Common Stock.
F2: The shares are held by the Francis P. McCormick Revocable Trust dated January 27, 2017, of which the Reporting Person is trustee.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 01, 2019 Filed Jul 3, 2019 20:14 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 290,476 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-019145 · doc4.xml · nonDerivative · entry 6 MCCORMICK FRANK · CIK 0001257809 · Chairman of Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,361,426 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · shares: Represents shares of restricted Common Stock issuable in the Reorganization in exchange for Management Incentive Units in the LLC held by the Reporting Person. The shares are subject to vesting at a rate of 1/60 per month from a vesting commencement date of February 12, 2019, such that the shares shall be fully vested on February 12, 2024, subject to the Reporting Person's continued service relationship to the Issuer through each vesting date. F1 · price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 20:14 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 418,016 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-019145 · doc4.xml · nonDerivative · entry 5 MCCORMICK FRANK · CIK 0001257809 · Chairman of Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,070,950 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · shares: Represents shares of restricted Common Stock issuable in the Reorganization in exchange for Management Incentive Units in the LLC held by the Reporting Person. The shares are subject to vesting at a rate of 1/60 per month from a vesting commencement date of August 15, 2017, such that the shares shall be fully vested on August 15, 2022, subject to the Reporting Person's continued service relationship to the Issuer through each vesting date. F1 · price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 20:14 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 406,723 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-019145 · doc4.xml · nonDerivative · entry 4 MCCORMICK FRANK · CIK 0001257809 · Chairman of Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 652,934 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · shares: Represents shares of restricted Common Stock issuable in the Reorganization in exchange for Management Incentive Units in the LLC held by the Reporting Person. The shares are subject to vesting at a rate of 1/60 per month from a vesting commencement date of March 26, 2016, such that the shares shall be fully vested on March 26, 2021, subject to the Reporting Person's continued service relationship to the Issuer through each vesting date. F1 · price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 20:14 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 66,729 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-019145 · doc4.xml · nonDerivative · entry 3 MCCORMICK FRANK · CIK 0001257809 · Chairman of Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,211 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · shares: Represents shares of Common Stock issuable in the Reorganization in exchange for Series B Preferred Units in the LLC held by the Reporting Person. F1 · price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 20:14 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 132,317 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-019145 · doc4.xml · nonDerivative · entry 2 MCCORMICK FRANK · CIK 0001257809 · Chairman of Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,482 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: Represents shares of restricted Common Stock issuable in the Reorganization in exchange for Common Units in the LLC held by the Reporting Person. The shares are subject to vesting at a rate of 1/60 per month from a vesting commencement date of May 6, 2015, such that the shares shall be fully vested on May 6, 2020, subject to the Reporting Person's continued service relationship to the Issuer through each vesting date. F1 · price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 20:14 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 47,165 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-019145 · doc4.xml · nonDerivative · entry 1 MCCORMICK FRANK · CIK 0001257809 · Chairman of Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,165 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Represents shares of Common Stock issuable in the Reorganization in exchange for Common Units in the LLC held by the Reporting Person. F1 · price: Immediately prior to the closing of the Issuer's initial public offering (the "IPO"), all units in BridgeBio Pharma LLC (the "LLC") held by the Reporting Person were exchanged for shares of Common Stock, par value $0.001 per share (the "Common Stock"), of the Issuer in an exempt transaction pursuant to Rules 16b-3, 16b-6 and 16b-7 (the "Reorganization"). In connection with the Reorganization, a wholly-owned subsidiary of the Issuer was merged with and into the LLC, and shares of Common Stock were allocated to the holders of outstanding units in the LLC pursuant to the distribution provisions of the Fourth Amended and Restated Limited Liability Company Agreement of the LLC, dated November 20, 2018, as amended, based upon the liquidation value of the LLC, assuming it was liquidated immediately prior to the closing of the IPO with a value implied by the IPO price of $17.00 per share. The LLC units have no expiration date. Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 17:23 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $6.60 | $0.00 |
DisclosureSEC source: 0001140361-18-027907 · doc1.xml · derivative · entry 1 MCCORMICK FRANK · CIK 0001257809 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-06-05 F1 · derivative.exercise_date: The shares subject to the Option will vest quarterly over one year from the grant date of June 6, 2018, such that the shares will be fully vested on the first anniversary of the date of grant. Read SEC document |
| June 08, 2017 Filed Jun 12, 2017 17:20 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | GrantStock Option (Right to Buy) · Derivative | 13,000 | $0.00 Strike: $10.55 | $0.00 |
DisclosureSEC source: 0001209191-17-039225 · doc4.xml · derivative · entry 1 MCCORMICK FRANK · CIK 0001257809 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2027-06-07 F1 · derivative.exercise_date: The shares subject to the Option will vest quarterly over one year from the grant date of June 8, 2017, such that the shares will be fully vested on the first anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.